AGENDA AT GLANCE
AGENDA AT GLANCE
Day 1
25th September 2025
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
Leadership Panel Discussion: Cell and Gene Therapy in East Asia: A Strategic Overview
9:00
Leadership Panel Discussion: Cell and Gene Therapy in East Asia: A Strategic Overview
- Leveraging East Asia’s innovation hubs to accelerate therapy development and commercialization.
- Overcoming supply chain and manufacturing challenges unique to the region.
- Opportunities for cross-border collaboration in research, clinical trials, and patient access.
Moderator:
👤 Bryan Choi, Professor, Inha University, Korea
Panellist:
👤 Ryu Kang, CSO, Vaxcell-Bio, Korea
👤 Kenji Nakamaru, VP, Head of R&D, Optieum Biotechnologies, Japan
👤 Phil Huang, Technical Director, Stemcyte, Taiwan
9:45
Path to Commercial Development of Cell and Gene Therapies in East Asia: Regulatory Landscape and Cross-border Collaboration.
- Recent trends in commercial development of cell and gene therapies in Asia
- Regulatory frameworks in Asia to increase patients' access
- Research infrastructure and collaboration on cell and gene therapies in Korea
👤 Bryan Choi, ISCT Asia Regional Vice-President and Professor, Inha University, South Korea
10:10
REGENECYTE, A Breakthrough Of Cord Blood Stem Cell Therapy
- Expanding applications of cord blood cell beyond oncology
- The Key staring material of allogeneic cell therapy
- The new era of cell therapy
👤 Phil Huang, Technical Director, Stemcyte, Taiwan
10:35
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Scaling Manufacturing for Cell & Gene Therapy: Optimizing Processes for Quality, Cost, and Speed
11:05
Advancements in Manufacturing Capabilities for Scalable Cell and Gene Therapies.
Key Topics:
- Implement Risk Assessment Tools to identify and mitigate potential hazards in CGT
- Optimize Manufacturing Processes by prioritizing critical control points for product safety and efficacy
- Align Production Strategies with regulatory requirements, ensuring continuous risk management throughout the product life cycle
👤 KwangJun Yoon, Managing Director, CHA Biotech, Korea
11:30
Next-Gen Dendritic Cell Immunotherapies: Bridging Innovation and Scalable Translation (TBC)
- Harnessing artificial nano dendritic cells to overcome immune resistance in solid tumors.
- Strategies for preclinical-to-clinical translation: from bench validation to GMP-compatible processes.
- Laying the groundwork for future scale-up: modular production approaches for emerging cell-based platforms.
👤 Sungjun Yoon, CEO, Fortuga Bio, South Korea
11:55
Revolution Cell Therapy Manufacturing: Advancements in Cell Culture Technology
- The role of encapsulation technology in modern cell culture techniques and understanding its applications and advantages.
- Exploring manufacturing challenges across various cell types by identifying and addressing critical gaps.
- The importance of quality, consistency and sterility in adopting innovative technologies for GMP manufacturing.
👤 Kazuchika Furuishi, Board of Director, CellFiber, Japan
12:20
Lunch Break, Exhibition Viewing & 1-1 Attendee Networking
CAR-T & CAR-NK Therapies in Oncology: Case Studies from East Asia
1:20
Development of 5th generation CAR-T cells Platform Technology
- Clinical challenge of multifunctional CLDN18.2-targeted CAR-T therapy targeting hard-to-treat solid tumours
- Design and manufacture of CARBio's innovative 5th generation CAR vectors
- Overcoming limitations of ex-vivo CAR-T therapies: Innovative in vivo CAR-T therapies
👤 Lee Heon Ju, CEO, CarBio Therapeutics, South Korea
1:45
The Role of scFv-CAR Optimization in Developing Functional CAR-T Therapies for Solid Tumors
- Optimized scFv-CAR enhances T-cell function & persistence
- The Eumbody System, an innovative screening platform for optimal CAR-T
- Lead product: OPTF01, anti FAPa CAR-T
👤 Kenji Nakamaru, VP, Head of R&D, Optieum Biotechnologies, Japan
2:10
The Present and Future of Anti-Cancer Immune Cell Therapy Based on NK Cell and CAR
- Vax NK cell therapy combined with HAIC demonstrates effective anti-tumor activity in Phase 2a trials for refractory advanced HCC.
- Monobody-based anti-PD-L1/hEphA2 CAR-T cells provide an effective strategy for targeting solid tumors.
- Anti-BCMA CAR-MILs/CAR-NK cells exhibit enhanced cytotoxicity against multiple myeloma, representing a powerful next-generation immunotherapy.
👤 Manh-Cuong Vo, General Manager, R&D Center, Vaxcell-Bio, South Korea
2:35
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
3:05
Clinical Development of CAR-T Cell Therapy for Hematologic Malignancy
- Phase I trial of UWC19 for R/R B-NHL
- Compassionate use of UWC19 for B cell hematologic malignancies
- Design of Phase II trial
👤 Cheng-Yi Jerry Kuo, Vice General Manager, UWELL Biopharma Co., Ltd., Taiwan
Gene Editing and CRISPR: Case Studies in Therapeutic Applications
3:30
Discovery and Engineering of a Novel Cas12a for Base Editing Applications
- Discovery and functional validation of a novel Cas12a ortholog
- Structure-based protein engineering using AlphaFold3 to enhance editing efficiency
- Development of a novel Cas12a-based base editor with multiplex editing capability
👤 Jaesuk Lee, Chief Scientific Officer, nSAGE, Korea
Advancing Genomic Medicine: Innovations in Polymer-Based Delivery Systems
3:55
Advancing Genomic Medicine: Innovations in Polymer-Based Delivery Systems
👤 Seokjoong Kim, Chief Strategy Officer, GenEdit, South Korea
Unlocking the Therapeutic Power of Extracellular Vesicles
4:20
Therapeutic Engineering of Extracellular Vesicles: From Cell Source Screening to Formulation Strategies
- Screening of diverse cell sources for EV production
- EV isolation, characterization, and functional enhancement via cell priming
- Drug formulation strategies to improve EV stability and therapeutic efficacy
👤 Chaemin Lim, Assistant Professor, College of Pharmacy & EV/Exosome Center, CHA University, South Korea
4:45
End of Conference Day 1
For Speaking Opportunities, Kindly Contact:
Umairoh Nurul Hafifa
Conference Producer
[email protected] | +62 856 0028 7725
Share With Your Network
